2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
Plan Sponsor Considerations for OTC-COVID 19 Tests Coverage
On January 10, 2022, guidance was released requiring group health plans and insurers to cover over-the-counter (OTC) COVID-19 diagnostic tests for members without cost…
Read Post
Spotlight on Utilization Management with Sharon Phares, PhD, MPH & Stephen Mackie
Utilization management (UM) programs are a vital tool in the clinical and cost management of drugs. These programs are offered in various forms by…
Read Post
PBM Implementation Results with Mandy Savino
Implementations can drastically impact overall satisfaction with a pharmacy benefit manager (PBM). Here are focused insights on how satisfied plans were with their PBM…
Read Post
NEW PRODUCT LAUNCH: Pharmaceutical Strategies Group Launches Artemetrx Rebate Monitor
NEW PRODUCT LAUNCH: Pharmaceutical Strategies Group Launches Artemetrx Rebate Monitor Improved oversight of PBM rebates via Artemetrx Rebate Monitor protects the financial interests…
Read Post
Five Things Plan Sponsors Need to Know About Specialty Drug Spend and Trend
Would you be surprised to learn specialty drug trend slowed in 2020 compared to recent years? Unfortunately, we know that the pandemic likely…
Read Post
Insights into the 2022 CVS Formulary Changes
CVS Health (CVS) announced their 2022 formulary changes, both exclusions and additions, stating the focus of their formulary strategy continues to be “providing access…
Read Post
Insights into Express Scripts 2022 NPF and Flex Formulary Changes
In recent weeks, Express Scripts (ESI) released their list of January 1, 2022 formulary changes for their National Preferred Formulary and National Preferred Flex…
Read Post
Betting on Biosimilars
It is a moment more than a decade in the making: biosimilars are finally gaining a notable presence in the biologics market in the…
Read Post
Proprietary Report on State of Specialty Spend and Trend Released by Pharmaceutical Strategies Group
Specialty trend increasing at a slower pace but maintains double-digit growth in PSG’s fifth annual integrated pharmacy and medical benefit report DALLAS, Tex. –…
Read Post
UPDATED: FDA Approves New Alzheimer’s Disease Drug
The FDA approval of Aduhelm on June 7, 2021, sparked both concern and confusion among stakeholders. There was skepticism that patients in all stages…
Read Post
Breaking News: New Weight Loss Drug, Wegovy™ (Semaglutide), Approved by FDA
What payers and plan sponsors need to know about the “most effective drug” for weight loss What is happening? Novo Nordisk announced the…
Read Post